Nephrology Reading List

  1. Hypertension in Chronic Kidney Disease
    1. Klahr S, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. NEJM. 1994; 330: 877-84.
    2. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (REIN). Lancet. 1997; 349: 1857-63.
    3. Wright JT, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288: 2421-31.
    4. Ruggenenti P, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365: 939-46.
    5. Hou FF, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. NEJM. 2006; 354: 131-40.
  2. Renal Osteodystrophy
    1. Suki, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients (DCOR). KI. 2007; 72: 1130-7.
  3. Anemia in Chronic Kidney Disease
    1. Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin (US Normal Hematocrit Study). NEJM. 1998; 339: 584-90.
    2. Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease (CHOIR). NEJM. 2006; 355: 2085-98.
    3. Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (TREAT). NEJM. 2009; 361: 2019-32.
  4. Management of Dyslipidemia in Chronic Kidney Disease
    1. Waner C, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis (4D Study). NEJM. 2005; 353: 238-48.
    2. Fellstrom BC, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis (AURORA). NEJM. 2009; 360: 1395-407.
    3. Biagent, C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 2181-92.
  5. Hemodialysis and Hemodialysis Access
    1. Eknoyan G, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis (HEMO). NEJM. 2002; 347: 2010-19.
  6. Peritoneal Dialysis and Peritonitis
    1. Paniagua R, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. JASN. 2002; 13: 1307-20.
  7. Acute Renal Failure and Critical Care Nephrology
    1. Vinsonneau C, et al. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006; 368: 379-85.
    2. Parienti JJ, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA. 2008; 299: 2413-22.
  8. Diabetic Nephropathy
    1. Lewis EJ, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. NEJM. 1993; 329: 1456-62.
    2. Estacio RO, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes (ABCD). Diabetes Care. 2000; 23: B54-64.
    3. Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). NEJM. 2001; 345: 851-60.
    4. Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). NEJM. 2001; 345: 861-9.
  9. Lupus Nephritis
    1. Appel, et al. Mycophenolate versus cyclophosphamide for induction treatment of lupus nephritis (ALMS). JASN. 2009; 20: 1103-12.
    2. Dooley, MA, et al. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. NEJM. 2011; 365:1886-95.
  10. IgA Nephropathy
    1. Pozzi, et al. Corticosteroids in IgA nephropathy: a randomized controlled trial. Lancett. 1999; 353: 883-7.
  11. Minimal Change/FSGS
    1. Cattran DC, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. KI. 1999; 56: 220-6.
  12. Membranous
    1. Ponticelli C, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. KI. 1995; 48: 1600-4.
  13. ANCA Vasculitis and Anti-GBM
    1. Jayne, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies (CYAZAREM). NEJM. 2003; 349: 36-44.
    2. Jayne, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis (MEPEX). JASN. 2007; 18: 2180-8.
  14. Other Glomerular Diseases
    1. Myeloma Kidney
      1. Clark WF, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143: 777-84.
    2. TTP
      1. Rock GA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic pupura. Canadian Apheresis Study Group. NEJM. 1991; 325: 393-7.
  15. Transplantation
    1. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983. 2: 986-9.
    2. Ekberg H, et al. Reduced exposure to calcineurin inhibitors in renal transplantation (ELITE-SYMPHONY Study). NEJM. 2007; 357: 2562-75.

Conferences

CUH Rotations (except MICU):
Morning Report – M-Thur 9AM
Noon Conference – M-Fri 12PM
Virtual Grand Rounds – Fri 8AM

PHHS Rotations (except MICU)
Morning Report – M-Thur 9AM
Noon Conference – M-Fri 12PM
Virtual Grand Rounds – Fri 8AM

VA Rotations (except CPICU):
Morning Report – M-Thur 9AM
Noon Conference – M-Fri 12PM
Virtual Grand Rounds – Fri 8AM

Virtual Morning Report and Noon Conference: Zoom Link

Chief Schedule

CHIEF RESIDENTS

PMH:

  • Hannah Blanchard
  • Michael Kimbrell

CUH:

  • Jonathan Meledez Torres
  • Kyle O'Malley

VA:

  • Caroline Abe
  • Angela Duvalyan

Chief Roles and Duties: Who to Contact

Webmail | On Call  | UT Southwestern | My UTSW 

Instagram @UTSWIM_Chiefs

Twitter

Comments or Concerns:

Department of Internal Medicine, Resident Program
5323 Harry Hines Boulevard, Dallas, Texas 75390-9030
Telephone 214-648-2287